Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis

Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis

Oct 20, 2014
Source URL: https://qa1.novartis.us/news/media-releases/novartis-announces-fda-advisory-committee-unanimously-recommends-approval-ain457-secukinumab-patients-moderate-severe-plaque-psoriasis-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-announces-fda-advisory-committee-unanimously-recommends-approval-ain457-secukinumab-patients-moderate-severe-plaque-psoriasis-0